Matinas biopharma announces infectious diseases society of america (idsa) has selected the enact phase 2 trial abstract of mat2203 as its outstanding abstract and idsa awardee for idweek 2022

Bedminster, n.j., oct. 19, 2022 (globe newswire) -- matinas biopharma holdings, inc. (nyse amer: mtnb), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (lnc) platform delivery technology, today announced that the infectious diseases society of america (idsa), one of the four sponsoring societies for idweek 2022, has selected the following abstract to be the idsa awardee as the outstanding abstract from a member in their specialty:
MTNB Ratings Summary
MTNB Quant Ranking